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This thesis was focused on hypoglycaemia as adverse drug reaction of rosiglitazone, 
pioglitazone, nateglinide and repaglinide, which have been launched to the UK market and on 
severe hypoglycaemia (SH) requiring the assistance of Emergency medical service (EMS) in 
region of Hradec Králové. Observed factors were described in two separate sections. 
 
Hypoglycaemia as adverse drug reaction of selected oral antidiabetics 
Aim 
 The aim of this study was to quantify the incidence of hypoglycaemic events during the 
first nine months of treatment with newly launched oral antidiabetics, rosiglitazone, 
pioglitazone, nateglinide or repaglinide, prescribed by general practitioners in England, to 
observe pattern of these events over time, to look for patients‘ characteristics which could 
influence the incidence of hypoglycaemia and to analyse the relationship between use of 




 We used data collected for prescription-event monitoring (PEM) studies of rosiglitazone, 
pioglitazone, nateglinide and repaglinide. PEM is an observational, non-interventional, cohort 
study. Incidence rate per 1000 patient-years of treatment was calculated for each drug cohort. 
Smoothed hazard estimate was plotted over time. The pattern of incident hypoglycaemic 
events was further analysed by Weibull model. „Case/non-case“ analysis was performed to 
compare patients who had at least one hypoglycaemic epizode in the first 9 months of 
treatment with those who did not. Cox proportional-hazards regression model was used to 
assess the relationship between patients‘ characteristics, use of concomitant anti-diabetic 
therapies and the incidence of hypoglycaemia in patients treated with pioglitazone. 
 
Results 
 The total number of observed patients was 14 373, 12 768, 4 549 and 5 727 in 
rosiglitazone, pioglitazone, nateglinide and repaglinide cohorts, respectively. From these, 276 
patients experienced at least one hypoglycaemic event. The IR of hypoglycaemia was 50% 
higher (IR=15,71/1000 patient-years) and 2 times higher (20,32/1000 patient-years) in 
patients treated with nateglinide and repaglinide, respectively, compared to those receiving 
treatment with thiazolidinediones (TZDs) (IR=9,94 and 9,64/1000 patient-years for patients 
treated with rosiglitazone and pioglitazone, respectively). Graph describing the occurence of 
incident hypoglycaemic events over time and the results of Weibull model (especially the 
value of shape parameter „p“) have shown that repaglinide and nateglinide-treated patients 
experienced significantly higher number of hypoglycaemic epizodes shortly after starting 
treatment. The hazard for patients treated with rosiglitazone and pioglitazone was 
approximately constant over time. Women receiving treatment with TZDs had 2 times the 
hazard of having hypoglycaemia than men did. 
 Results of Cox proportional-hazards regression model have shown that patients taking 
pioglitazone and sulphonylurea combination therapy and pioglitazone and insulin 
combination therapy had 3 and 4 times the hazard of having hypoglycaemia compared to 
those who were not taking these adjunctive therapies [HR=3,11 (CI 1,64, 5,88); HR=4,15 (CI 
1,74, 9,91), respectively]. Patients taking the adjunctive metformin were 25% less likely to 
experince hypoglycaemia compared with those who did not take adjunctive metformin 
(HR=0,75; CI 0,44, 1,27). 
 
Conclusion 
 Results of this study have shown that the incidence of hypoglycaemia in observed cohorts 
is relatively low. Patients treated with nateglinide or repaglinide are in higher risk of having 
hypoglycaemia compared to those who are taking TZDs. Furthermore patients receiving the 
combination therapy of pioglitazone and sulphonylurea or insulin have also higher hazard of 
having hypoglycaemia compared to those who are not taking these adjunctive therapies. The 
beginning of treatment with nateglinide or repaglinide was associated with higher incidence 
of hypoglycaemia signalizing the necessity of patient adaptation on new therapy to assure the 
optimal blood glucose control concurrently with minimalization of hypoglycaemia occurence. 
Further investigation is necessary to assess whether women receiving TZDs are more prone to 
hypoglycaemia than men. 
 
Severe hypoglycaemia requiring the assistance of Emergency medical service in the 
region of Hradec Králové 
Aim 
 The aim of this study was to quantify the incidence of SH requiring the assistance of EMS 
in the region of Hradec Králové, to describe the occurence of these epizodes during the day, 
to look for symptoms and causes which have statistically significant relationship with blood 
glucose level and to observe therapy of hypoglycaemia, termination of EMS action because of 
hypoglycaemia and other parameters. 
 
Methods 
 Data for analysis were obtained by filling the patients' documentary lists by medical staff 
of EMS. Incidence of SH per 100 patient-years was calculated based on number of patients 
with type 1 and type 2 diabetes mellitus (DM) in region of Hradec Králové. Distribution of 
hypoglycaemic epizodes over the day was presented by graph and was analysed using 
contingency tables. General linear model and Regression trees technique were used to assess 




 During year 2007 there were 338 hypoglycaemic epizodes requiring the assistance of EMS 
in the region of Hradec Králové (1,2% of all tours of EMS in this region) recorded in 262 
patients. Nearly one half of these events (n=150) appeared in 125 type 2. diabetic patients and 
83 episodes were recorded in 42 type 1 diabetic patients. Type of DM was not specified in 
103 epizodes. Incidence of SH was 2,4 and 0,4/100 patient-years in patients with type 1 and 
type 2 DM, respectively. The most epizodes appeared in the afternoon, between 2 pm and 6 
pm (p<0,001). Almost one third of observed patients had impaired consciousness and 27% 
were in coma. 68% of patients did not aware of developping hypoglycaemia. The lowest 
glycaemia was measured out in patients who experienced unconsciousness and severe 
perspiration together. Food deficiency, insulin and physical activity belonged among the most 
frequently identified causes of SH. Among causes which led to significantly lower blood 
glucose levels compared to those who did not record these causes belonged insulin and 
alcohol consumption. Almost 90% of patients were treated with glucose i.v., glucagon was 
applied in 9 cases. Only 14 patients from 262 had glucagon at home. Nearly one third of 
patients (n=95) was hospitalized. 
 
Conclusion 
 Hypoglycaemia represents important percentage of all epizodes requirig the assistance of 
EMS. Severe hypoglycaemia is more frequent in type 1 diabetic patients. The most critical 
period of the day for hypoglycaemia is in the afternoon, between 2 pm and 6 pm. Patients 
with type 1 DM should also thoroughly follow recommendation about therapy regime with 
regard to higher risk of hypoglycaemia during the night, between 10 pm and 2 am. Diabetic 
patients should always be informed about the risk associated with alcohol consumption. To 
minimise the frequency of SH, the necessity of meal in accordance with anti-diabetic 
treatment and exercise should be emphasized all the time. More frequent usage of glucagon 
by patients' relatives could minimize the incidence of SH requiring the assistance of EMS. 
 
